• FirefoxInstall the new Firefox »
  •  Dow Up0.19% Nasdaq Up0.57%

    Novavax, Inc. (NVAX)

    8.22 Up 0.64(8.44%) Mar 27, 4:00PM EDT
    |After Hours : 8.27 Up 0.05 (0.61%) Mar 27, 7:03PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Novavax, Inc.
    20 Firstfield Road
    Gaithersburg, MD 20878
    United States - Map
    Phone: 240-268-2000
    Website: http://www.novavax.com

    Index Membership:N/A
    Full Time Employees:308

    Business Summary 

    Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, as well as pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, as well as rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Novavax, Inc.

    Corporate Governance 
    Novavax, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 8. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Stanley C. Erck , 67
    Chief Exec. Officer, Pres, Director and Member of Fin. Committee
    Mr. Barclay A. Phillips , 52
    Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer
    Dr. Gregory M. Glenn M.D., 61
    Sr. VP of Corp. Devel.
    Dr. Timothy Jon Hahn Ph.D., 51
    Sr. VP of Global Manufacturing Operations
    Mr. John Joseph Trizzino B.S., M.B.A., 55
    Sr. VP of Commercial Operations
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders